0.95
price up icon0.54%   0.0051
 
loading
Immunic Inc stock is traded at $0.95, with a volume of 1.07M. It is up +0.54% in the last 24 hours and up +1.48% over the past month. Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.9449
Open:
$0.95
24h Volume:
1.07M
Relative Volume:
0.66
Market Cap:
$93.72M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.4502
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
+5.39%
1M Performance:
+1.48%
6M Performance:
-25.20%
1Y Performance:
-37.50%
1-Day Range:
Value
$0.9303
$0.9638
1-Week Range:
Value
$0.87
$1.00
52-Week Range:
Value
$0.561
$2.11

Immunic Inc Stock (IMUX) Company Profile

Name
Name
Immunic Inc
Name
Phone
(332) 255-9818
Name
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Name
Employee
90
Name
Twitter
@ImmunicInc
Name
Next Earnings Date
2025-03-17
Name
Latest SEC Filings
Name
IMUX's Discussions on Twitter

Compare IMUX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMUX
Immunic Inc
0.95 96.53M 0 -93.61M -71.16M -2.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Immunic Inc Stock (IMUX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-25-25 Initiated William Blair Outperform
Nov-25-24 Initiated H.C. Wainwright Buy
Sep-09-24 Resumed Leerink Partners Outperform
Aug-27-24 Initiated B. Riley Securities Buy
Oct-21-22 Downgrade SVB Leerink Outperform → Mkt Perform
Sep-19-22 Resumed H.C. Wainwright Buy
Apr-15-21 Initiated Aegis Capital Buy
Mar-24-21 Initiated JMP Securities Mkt Outperform
Oct-02-20 Initiated SVB Leerink Outperform
Aug-26-20 Initiated Piper Sandler Overweight
Aug-07-20 Resumed ROTH Capital Buy
Jul-20-20 Initiated BMO Capital Markets Outperform
Jun-05-20 Initiated Wedbush Outperform
May-11-20 Initiated H.C. Wainwright Buy
Mar-25-20 Initiated ROTH Capital Buy
Jul-11-19 Initiated Chardan Capital Markets Buy
View All

Immunic Inc Stock (IMUX) Latest News

pulisher
Aug 20, 2025

Immunic to Participate in Investor, Scientific and Industry Conferences in June - MSN

Aug 20, 2025
pulisher
Aug 15, 2025

Will Immunic Inc. benefit from geopolitical trendsInflation Watch & Consistent Profit Trade Alerts - thegnnews.com

Aug 15, 2025
pulisher
Aug 14, 2025

Bollinger Bands Show Potential Breakout in Immunic Inc.2025 Support & Resistance & AI Powered Market Entry Strategies - classian.co.kr

Aug 14, 2025
pulisher
Aug 14, 2025

Immunic Inc.’s Beta Climbs After Market VolatilityWeekly Volume Report & Growth Focused Entry Point Reports - kangso.co.kr

Aug 14, 2025
pulisher
Aug 12, 2025

What are the future prospects of Immunic Inc.July 2025 Intraday Action & Consistent Return Strategy Ideas - thegnnews.com

Aug 12, 2025
pulisher
Aug 12, 2025

Immunic (IMUX) Q2 Loss Widens 25% - AOL.com

Aug 12, 2025
pulisher
Aug 12, 2025

Momentum Screeners Rank Immunic Inc. in Top 5 TodayCapital Protection Trading Strategies Gain Interest - beatles.ru

Aug 12, 2025
pulisher
Aug 12, 2025

H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data - Investing.com

Aug 12, 2025
pulisher
Aug 12, 2025

H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data By Investing.com - Investing.com South Africa

Aug 12, 2025
pulisher
Aug 12, 2025

Immunic, Inc. Advances Multiple Sclerosis Drug Trials - TipRanks

Aug 12, 2025
pulisher
Aug 11, 2025

Immunic, Inc. shares rise 3.21% premarket after Novartis' positive Phase III trial results for ianalumab in Sjögren's disease. - AInvest

Aug 11, 2025
pulisher
Aug 10, 2025

William Blair Maintains Immunic(IMUX.US) With Buy Rating - 富途牛牛

Aug 10, 2025
pulisher
Aug 10, 2025

Is Immunic Inc. stock a value trapInvestment Timing Signals - mustnews.co.kr

Aug 10, 2025
pulisher
Aug 10, 2025

Technical signs of recovery in Immunic Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser

Aug 10, 2025
pulisher
Aug 09, 2025

Will Immunic Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Intraday pattern recognizer results for Immunic Inc.Free Early Entry Tips With Low Risk Zone - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Immunic reports promising Phase 2 data for lead drug candidate in progressive MSICYMI - Proactive financial news

Aug 09, 2025
pulisher
Aug 09, 2025

Is a relief rally coming for Immunic Inc. holdersConservative Investment Setup and Risk Analysis - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

Immunic Advances Phase 3 Trials and Financial Health - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

Immunic: Q2 Earnings Snapshot - Connecticut Post

Aug 08, 2025
pulisher
Aug 07, 2025

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Malaysian Reserve

Aug 07, 2025
pulisher
Aug 07, 2025

Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Small cap wrap: Immunic, Nextech3D.ai, EDM Resources, Alvopetro… - Proactive Investors

Aug 07, 2025
pulisher
Aug 07, 2025

Immunic Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Immunic CEO on strong Q2 progress with vidofludimus calcium trials for MS - Proactive financial news

Aug 07, 2025
pulisher
Aug 07, 2025

Immunic CEO Discusses Strong Q2 Progress in Vidofludimus Calcium Trials for MS Treatment - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Immunic advances MS drug program with Phase 3 trials fully enrolled - Proactive financial news

Aug 07, 2025
pulisher
Aug 07, 2025

Immunic Q2 net loss widens, flags potential cash raise - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Biotech Immunic Q2 net loss widens, flags need to raise cash - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Immunic, Inc.: A High-Potential Biotech Play in the MS and GI Therapeutics Space - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Ariva

Aug 07, 2025
pulisher
Aug 07, 2025

Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World

Aug 07, 2025
pulisher
Aug 06, 2025

Immunic, Inc. shares fall 1.43% after-hours as ImmunoPrecise Antibodies Ltd. reports earnings miss and auditor raises 'going concern' doubt. - AInvest

Aug 06, 2025
pulisher
Aug 05, 2025

Immunic Inc. May Stage Comeback if Support HoldsAnalysts Use RSI to Predict UPLD’s Next MoveSecure Return Focused Investment Plan Released - beatles.ru

Aug 05, 2025
pulisher
Aug 04, 2025

Immunic, Inc. shares fall 2.36% premarket after Sonnet BioTherapeutics' clinical trial data shows potential for SON-1010 in ovarian cancer. - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Immunic Inc. Stock Analysis and ForecastBreakout profit opportunities - Jammu Links News

Aug 04, 2025
pulisher
Aug 04, 2025

When is Immunic Inc. stock expected to show significant growthMarket-crushing stock picks - Jammu Links News

Aug 04, 2025
pulisher
Aug 03, 2025

How does Immunic Inc. compare to its industry peersMaximize gains with proven stock analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of Immunic Inc. stockMaximize returns with strategic portfolio planning - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Should I hold or sell Immunic Inc. stock in 2025Invest confidently with real-time data analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Immunic Inc. stockSuperior profit margins - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Immunic Inc. in the next 12 monthsTrack high-yield stocks before they peak - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Immunic Inc. stockUnstoppable investment returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What drives Immunic Inc. stock priceGain access to exclusive stock analysis - Jammu Links News

Aug 03, 2025

Immunic Inc Stock (IMUX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immunic Inc Stock (IMUX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Tardio Jason
President and COO
Jun 05 '25
Buy
0.79
12,512
9,884
12,512
Vitt Daniel
CEO and Director
Jun 04 '25
Buy
0.77
15,000
11,550
29,000
Neermann Joerg
Director
Jun 04 '25
Buy
0.77
70,000
53,900
170,000
Neermann Joerg
Director
Jun 05 '25
Buy
0.76
30,000
22,800
200,000
Whaley Glenn
Chief Financial Officer
Jun 03 '25
Buy
0.71
45,000
32,076
95,510
Rudick Richard Alan
Director
Jun 03 '25
Buy
0.70
143,075
100,024
230,375
Rudick Richard Alan
Director
Nov 12 '24
Buy
1.15
87,300
100,369
87,300
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):